The chemosensitivity of testicular germ cell tumors

Cellular Oncology

Volumn 37, Issue 2, 2014, Pages 79-94

  Voutsadakis, Ioannis A ^a  

^a Sault Area Hospitals   (Canada)

Author keywords

Chemotherapy; Non seminoma; Oct4; p53; Resistance; Seminoma; Sensitivity; Testicular germ cell tumors

Indexed keywords

BLEOMYCIN; CISPLATIN; DABRAFENIB; MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN; PROTEIN P21; PROTEIN P53; VEMURAFENIB; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CHROMOSOME 12; CHROMOSOME 12P; DEL CASTILLO SYNDROME; DNA DAMAGE; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEMINOMA; SUMOYLATION; TESTIS DEVELOPMENT; TESTIS DISEASE; CELL CYCLE CHECKPOINT; DRUG EFFECTS; MALE; METABOLISM; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; TESTICULAR NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899658920     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0168-6     Document Type: Review

References (157)

1. A. Di Pietro, E.G.E. de Vries, J.A. Gietema, D.C.J. Spierings, S. de Jong, Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours. Int. J. Biochem. Cell Biol. 37, 2437-2456 (2005)
2. L.H.J. Looijenga, A.J.M. Gillis, H. Stoop, K. Biermann, J.W. Oosterhuis, Dissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance. Int. J. Androl. 34, e234-e251 (2011)
3. International Germ Cell Cancer Collaborative Group, International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15, 594-603 (1997)
4. F. Mayer, F. Honecker, L.H.J. Looijenga, C. Bokemeyer, Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann. Oncol. 14, 825-832 (2003)
5. H.Q. Peng, D. Hogg, D. Malkin, D. Bailey, B.L. Gallie, M. Balbul, M. Jewett, J. Buchanan, P.E. Goss, Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 53, 3574-3578 (1993)
6. L. Guillou, A. Estreicher, P. Chaubert, J. Hurlimann, A.M. Kurt, G. Metthez, R. Iggo, A.C. Gray, P. Jichlinski, H.-J. Leisinger, J. Benhattar, Germ cell tumors of the testis overexpress wild-type p53. Am. J. Pathol. 149, 1221-1228 (1996)
7. J.S. Kerley-Hamilton, A.M. Pike, N. Li, J. DiRenzo, M.J. Spinella, A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24, 6090-6100 (2005)
8. S. Nag, J. Qin, K.S. Srivenugopal, M. Wang, The MDM2-p53 pathway revisited. J Biomed Res 27, 254-271 (2013)
9. C.R. Leemans, B.J.M. Braakhuis, R.H. Brakenhoff, The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22 (2011)
10. I.A. Voutsadakis, Ubiquitination and the ubiquitin-proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma. Anticancer Res. 33, 3527-3541 (2013)
11. A.V. Pinho, I. Rooman, F.X. Real, p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 10, 1312-1321 (2011)
12. S. Carter, K.H. Vousden, A role for Numb in p53 stabilization. Genome Biol. 9, 221 (2008)
13. I.N. Colaluca, D. Tosoni, P. Nuciforo, F. Senic-Matuglia, V. Galimberti, G. Viale, S. Pece, P.P. Di Fiore, NUMB controls p53 tumour suppressor activity. Nature 451, 76-80 (2008)
14. M. Oren, V. Rotter, Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107 (2010)
15. L.A. Carvajal, J.J. Manfredi, Another fork in the road- life or death decisions by the tumour suppressor p53. EMBO Rep. 14, 414-421 (2013)
16. H. Solomon, S. Madar, V. Rotter, Mutant p53 gain of function is interwoven into the hallmarks of cancer. J. Pathol. 225, 475-478 (2011)
17. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011)
18. P. Campomenosi, P. Monti, A. Aprile, A. Abbondandolo, T. Frebourg, B. Gold, T. Crook, A. Inga, M.A. Resnick, R. Iggo, G. Fronza, p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20, 3573-3579 (2001)
19. S. Rowan, R.L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, K.H. Vousden, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15, 827-838 (1996)
20. G. Blandino, W. Deppert, P. Hainaut, A. Levine, G. Lozano, M. Olivier, V. Rotter, K. Wiman, M. Oren, Mutant p53 protein, master regulator of human malignancies: a report of the fifth Mutant p53 Workshop. Cell Death Differ. 19, 180-183 (2012)
21. J.G. Jackson, S.M. Post, G. Lozano, Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J. Pathol. 223, 127-136 (2011)
22. K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb, K.H. Vousden, TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006)
23. F. Mayer, H. Stoop, G.L. Scheffer, R. Scheper, J.W. Oosterhuis, L.H.J. Looijenga, C. Bokemeyer, Molecular determinants of treatment response in human germ cell tumors. Clin. Cancer Res. 9, 767-773 (2003)
24. Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene 23, 4862-4872 (2004)
25. A. Di Pietro, R. Koster, W. Boersma-van Eck, W.A. Dam, N.H. Mulder, J.A. Gietema, E.G.E. de Vries, S. de Jong, Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cell Cycle 11, 4552-4562 (2012)
26. M. Gutekunst, M. Oren, A. Weilbacher, M.A. Dengler, C. Markwardt, J. Thomale, W.E. Aulitzky, H. van der Kuip, p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS ONE 6, e19198 (2011)
27. C. Dai, W. Gu, p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 16, 528-535 (2010)
28. M. Wade, Y.V. Wang, G.M. Wahl, The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20, 299-309 (2010)
29. J.M. Stommel, G.M. Wahl, A new twist in the feedback loop. Stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4, 413-417 (2005)
30. B. Li, Q. Cheng, Z. Li, J. Chen, p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle 9, 1411-1420 (2010)
31. J.T. Lee, W. Gu, The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17, 86-92 (2010)
32. J. Yuan, K. Luo, L. Zhang, J.C. Cheville, Z. Lou, USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396 (2010)
33. M.B. Kastan, G.P. Zambetti, Parc-ing p53 in the cytoplasm. Cell 112, 1-5 (2003)
34. A.Y. Nikolaev, M. Li, N. Puskas, J. Qin, W. Gu, Parc: a cytoplasmic anchor for p53. Cell 112, 29-40 (2003)
35. R.P. Leng, Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J.M. Parant, G. Lozano, R. Hakem, S. Benchimol, Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003)
36. D. Chen, N. Kon, M. Li, W. Zhang, J. Qin, W. Gu, ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121, 1071-1083 (2005)
37. D. Dornan, I. Wertz, H. Shimizu, D. Arnott, G.D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, V.M. Dixit, The ubiquitin ligase COP is a critical negative regulator of p53. Nature 429, 86-92 (2004)
38. S.V. Khoronenkova, G.L. Dianov, USP7S-dependent inactivation of Mule regulates DNA damage signalling and repair. Nucleic Acids Res. 41, 1750-1756 (2013)
39. Q. Zhong, W. Gao, F. Du, X. Wang, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095 (2005)
40. A. Shmueli, M. Oren, Life, death, and ubiquitin: taming the Mule. Cell 121, 963-965 (2005)
41. N. Taira, K. Nihira, T. Yamaguchi, Y. Miki, K. Yoshida, DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 25, 725-738 (2007)
42. C. Rinaldo, A. Prodosmo, F. Mancini, S. Iacovelli, A. Sacchi, F. Moretti, S. Soddu, MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol. Cell 25, 739-750 (2007)
43. S.M. Sykes, H.S. Mellert, M.A. Holbert, K. Li, R. Marmorstein, W.S. Lane, S.B. McMahon, Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841-851 (2006)
44. Y. Tang, J. Luo, W. Zhang, W. Gu, Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24, 827-839 (2006)
45. S.M. Sykes, T.J. Stanek, A. Frank, M.E. Murphy, S.B. McMahon, Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J. Biol. Chem. 284, 20197-20205 (2009)
46. C.D. Knights, J. Di Catania, S. Giovanni, S. Muratoglu, R. Perez, A. Swartzbeck, A.A. Quong, X. Zhang, T. Beerman, R.G. Pestell, M.L. Avantaggiati, Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173, 533-544 (2006)
47. J. Luo, A.Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, W. Gu, Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-148 (2001)
48. J. Yi, J. Luo, SIRT1 and p53, effect on cancer, senescence and beyond. Biochim. Biophys. Acta 2010, 1684-1689 (1804)
49. M. Han, E. Song, Y. Guo, X. Ou, C. Mantel, H.E. Broxmeyer, SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2, 241-251 (2008)
50. M. Miettinen, I. Virtanen, A. Talerman, Intermediate filament proteins in human testis and testicular germ-cell tumors. Am. J. Pathol. 120, 402-410 (1985)
51. M.A. Calzado, L. De La Vega, E. Munoz, M.L. Schmitz, From top to bottom. The two faces of HIPK2 for regulation of the hypoxic response. Cell Cycle 8, 1659-1664 (2009)
52. A.S. Coutts, L. Weston, N.B. La Thangue, Actin nucleation by a transcription co-factor that links cytoskeletal events with the p53 response. Cell Cycle 9, 1511-1515 (2010)
53. N. Shikama, C.-W. Lee, S. France, L. Delavaine, J. Lyon, M. Krstic-Demonacos, N.B. La Thangue, A novel cofactor for p300 that regulates the p53 response. Mol. Cell 4, 365-376 (1999)
54. A. Sullivan, X. Lu, ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 96, 196-200 (2007)
55. Y. Samuels-Lev, D.J. O'Connor, D. Bergamaschi, G. Trigiante, J.-K. Hsieh, S. Zhong, I. Campargue, L. Naumovski, T. Crook, X. Lu, ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794 (2001)
56. S. Gillotin, X. Lu, The ASPP proteins complex and cooperate with p300 to modulate the transcriptional activity of p53. FEBS Lett. 585, 1778-1782 (2011)
57. L. Yuan, C. Tian, H. Wang, S. Song, D. Li, G. Xing, Y. Yin, F. He, L. Zhang, Apak competes with p53 for direct binding to intron 1 of p53AIP1 to regulate apoptosis. EMBO Rep. 13, 363-370 (2012)
58. C. Tian, G. Xing, P. Xie, K. Lu, J. Nie, J. Wang, L. Li, M. Gao, L. Zhang, F. He, KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. Nat. Cell Biol. 11, 580-591 (2009)
59. L. Cheng, M.-T. Sung, P. Cossu-Rocca, T.D. Jones, G.T. MacLennan, J. De Jong, A. Lopez-Beltran, R. Montironi, L.H.J. Looijenga, OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J. Pathol. 211, 1-9 (2007)
60. S. Stefanovic, M. Pucéat, L'octamanie continue. Le double jeu de OCT4. Med. Sci 26, 411-416 (2010)
61. J. Kehler, E. Tolkunova, B. Koschorz, M. Pesce, L. Gentile, M. Boiani, Oct4 is required for primordial germ cell survival. EMBO Rep. 5, 1078-1083 (2004)
62. S. Stefanovic, N. Abboud, S. Désilets, D. Nury, C. Cowan, M. Pucéat, Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate. J. Cell Biol. 186, 665-673 (2009)
63. Y.H. Huang, C.C. Chin, H.N. Ho, C.K. Chou, C.N. Shen, H.C. Kuo, Y.C. Wu, Y.C. Hung, C.C. Chang, T.Y. Ling, Pluripotency of mouse spermatogonial stem cells maintened by IGF-1-dependent pathway. FASEB J. 23, 2076-2087 (2009)
64. Y. Lin, Y. Yang, W. Li, Q. Chen, J. Li, X. Pan, L. Zhou, C. Liu, C. Chen, J. He, H. Cao, H. Yao, L. Zheng, X. Xu, Z. Xia, J. Ren, L. Xiao, L. Li, B. Shen, H. Zhou, Y.-J. Wang, Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol. Cell 48, 627-640 (2012)
65. P. Deb-Rinker, D. Ly, A. Jezierski, M. Sikorska, P.R. Walker, Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation. J. Biol. Chem. 280, 6257-6260 (2005)
66. Y.C. Wu, T.Y. Ling, S.H. Lu, H.C. Kuo, H.N. Ho, S.D. Yeh, C.N. Shen, Y.H. Huang, Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res. 72, 4963-4973 (2012)
67. T.D. Jones, T.M. Ulbright, J.N. Eble, L.A. Baldridge, L. Cheng, OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am. J. Surg. Pathol. 28, 935-940 (2004)
68. G. Pan, J.A. Thomson, Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 17, 42-49 (2007)
69. L. Mándoky, B. Szende, L. Géczi, I. Bodrogi, M. Kásler, M. Bak, Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment. Anticancer Res. 28, 1641-1650 (2008)
70. D. Juric, S. Sale, R.A. Hromas, R. Yu, Y. Wang, G.E. Duran, R. Tibshirani, L.H. Einhorn, B.I. Sikic, Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc. Natl. Acad. Sci. U. S. A. 102, 17763-17768 (2005)
71. M.W. Datta, E. Macri, S. Signoretti, A.A. Renshaw, M. Loda, Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod. Pathol. 14, 437-442 (2001)
72. R. Koster, A. di Pietro, H. Timmer-Bosscha, J.H. Gibcus, A. van den Berg, A.J. Suurmeijer, R. Bischoff, J.A. Gietema, S. de Jong, Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 120, 3594-3605 (2010)
73. T. Mueller, L.P. Mueller, J. Luetzkendorf, W. Voigt, H. Simon, H.J. Schmoll, Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 27, 71-83 (2006)
74. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010)
75. I.A. Voutsadakis, Molecular predictors of gemcitabine response in pancreatic cancer. World J. Gastrointest. Oncol. 3, 153-164 (2011)
76. L.-L. Tsai, C.-C. Yu, Y.-C. Chang, C.-H. Yu, M.-Y. Chou, Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J. Oral Pathol. Med. 40, 621-628 (2011)
77. N.S. Hillbertz, J.M. Hirsch, J. Jalouli, M.M. Jalouli, L. Sand, Viral and molecular aspects of oral cancer. Anticancer Res. 32, 4201-4212 (2012)
78. J. Houldsworth, H. Xiao, V.V.V.S. Murty, W. Chen, B. Ray, V.E. Reuter, G.J. Bosl, R.S.K. Chaganti, Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16, 2345-2349 (1998)
79. T. Mueller, L.P. Mueller, H.-J. Holzhausen, R. Witthuhn, P. Albers, H.J. Schmoll, Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochem. Cell Biol. 134, 197-204 (2010)
80. K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006)
81. N. Tapia, H.R. Scholer, p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med. 207, 2045-2048 (2010)
82. R.R. Chivukula, J.T. Mendell, Abate and switch: miR-145 in stem cell differentiation. Cell 137, 606-608 (2009)
83. P. Svoboda, M. Flemr, The role of miRNAs and endogenous siRNAs in maternal-to-zygotic reprogramming and the establishment of pluripotency. EMBO Rep. 11, 590-597 (2010)
84. L. Liu, J. Lian, H. Zhang, H. Tian, M. Liang, M. Yin, F. Sun, Micro-RNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J. Cell. Physiol. 228, 2294-2304 (2013)
85. N. Xu, T. Papagiannakopoulos, G. Pan, J.A. Thomson, K.S. Kosik, MicroRNA-145 regulates OCT4, SOX2 and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137, 647-658 (2009)
86. S.O. Suh, Y. Chen, M.S. Zaman, H. Hirata, S. Yamamura, V. Shahryari, J. Liu, Z.L. Tabatabai, S. Kakar, G. Deng, Y. Tanaka, R. Dahiya, MicroRNA-145 is regulated by methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32, 772-778 (2011)
87. N. Riggi, M.-L. Suvà, C. De Vito, P. Provero, J.-C. Stehle, K. Baumer, L. Cironi, M. Janiszewska, T. Petricevic, D. Suvà, S. Tercier, J.-M. Joseph, L. Guillou, I. Stamenkovic, EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 24, 916-932 (2010)
88. C. Krausz, L.H.J. Looijenga, Genetic aspects of testicular germ cell tumors. Cell Cycle 7, 3519-3524 (2008)
89. F. Anokye-Danso, C.M. Trivedi, D. Juhr, M. Gupta, Z. Cui, Y. Tian, Y. Zhang, W. Yang, P.J. Gruber, J.A. Epstein, E.E. Morrisey, Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8, 376-388 (2011)
90. S.-L. Lin, Concise review: deciphering the mechanism behind induced pluripotent stem cell generation. Stem Cells 29, 1645-1649 (2011)
91. D.K. Ma, J.U. Guo, G. Ming, H. Song, DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 8, 1526-1531 (2009)
92. P.M. Voorhoeve, C. le Sage, M. Schrier, A.J.M. Gillis, H. Stoop, R. Nagel, Y.-P. Liu, J. van Duijse, J. Drost, A. Griekspoor, E. Zlotorynski, N. Yabuta, G. De Vita, H. Nojima, L.H.J. Looijenga, R. Agami, A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181 (2006)
93. M.L. Wang, S.H. Chiou, C.W. Wu, Targeting cancer stem cells: emerging role of Nanog transcription factor. Oncol. Targets Ther. 6, 1207-1220 (2013)
94. P. Navarro, P. Avner, When X-inactivation meets pluripotency: an intimate rendezvous. FEBS Lett. 583, 1721-1727 (2009)
95. A.H. Hart, L. Hartley, K. Parker, M. Ibrahim, L.H.J. Looijenga, M. Pauchnik, C.W. Chow, L. Robb, The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 104, 2092-2098 (2005)
96. P.E. Szabo, K. Hubner, H. Scholer, J.R. Mann, Allele-specific expression of imprinted genes in mouse migratory primordial germ cells. Mech. Dev. 115, 157-160 (2002)
97. D. Gilbert, E. Rapley, J. Shipley, Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nat. Rev. Cancer 11, 278-288 (2011)
98. M. Kucia, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, M.Z. Ratajczak, Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894 (2005)
99. M.C. Mostert, A.J.M.H. Verkerk, M. van de Pol, J. Heighway, P. Marynen, C. Rosenberg, A. Geurts van Kessel, J. van Echten, B. de Jong, J.W. Oosterhuis, L.H.J. Looijenga, Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 16, 2617-2627 (1998)
100. S. Rodriguez, O. Jafer, H. Goker, B.M. Summersgill, G. Zafarana, A.J.M. Gillis, R.J.H.L.M. van Gurp, J.W. Oosterhuis, Y.-J. Lu, R. Huddart, C.S. Cooper, J. Clark, L.H.J. Looijenga, J.M. Shipley, Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22, 1880-1891 (2003)
101. J.E. Korkola, J. Houldsworth, R.S.V. Chadalavada, A.B. Olshen, D. Dobrzynski, V.E. Reuter, G.J. Bosl, R.S.K. Chaganti, Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 66, 820-827 (2006)
102. K. Tanaka, S. Okamoto, Y. Ishikawa, H. Tamura, T. Hara, DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene 28, 2142-2151 (2009)
103. C.J. Giuliano, J.S. Kerley-Hamilton, T. Bee, S.J. Freemantle, R. Manickaratnam, E. Dmitrovsky, M.J. Spinella, Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim. Biophys. Acta 1731, 48-56 (2005)
104. E. Rajpert-De Meyts, R. Hanstein, N. Jorgensen, N. Graem, P.H. Vogt, N.E. Skakkebaek, Developmental expression of POU5F1 (OCT-3/4) in normal and dysgenetic human gonads. Hum. Reprod. 19, 1338-1344 (2004)
105. M. Cools, S.L.S. Drop, K.P. Wolfenbuttel, J.W. Oosterhuis, L.H.J. Looijenga, Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr. Rev. 27, 468-484 (2006)
106. K. McClelland, J. Bowles, P. Koopman, Male sex determination: insights into molecular mechanisms. Asian J. Androl. 14, 164-171 (2012)
107. J.S. Fisher, Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. Reproduction 127, 305-315 (2004)
108. F. Orso, E. Cottone, M.D. Hasleton, Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the5′-untranslated region. Biochem. J. 377, 429-438 (2004)
109. D. Eckert, S. Buhl, S. Weber, R. Joger, H. Schorle, The AP-2 family of transcription factors. Genome Biol. 6, 246 (2005)
110. S. Schofer, J. Anschlag, D. Nettersheim, N. Haas, L. Pawig, H. Schorle, The role of BLIMP1 and its putative downstream target TFAP2C in germ cell development and germ cell tumours. Int. J. Androl. 34, e152-e159 (2011)
111. C.E. Hoei-Hansen, J.E. Nielsen, K. Almstrup, S.B. Sonne, N. Graem, N.E. Skakkebaek, H. Leffers, E. Rajpert-De Meyts, Transcription Factor AP-2γ is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin. Cancer Res. 10, 8521-8530 (2004)
112. A. Jørgensen, J.E. Nielsen, M. Blomberg Jensen, N. Graem, E. Rajpert-De Meyts, Analysis of meiosis regulators in human gonads: a sexually dimorphic spatio-temporal expression pattern suggests involvement of DMRT1 in meiotic entry. Mol. Hum. Reprod. 18, 523-534 (2012)
113. A. Jørgensen, J.E. Nielsen, K. Almstrup, B.G. Toft, B.L. Petersen, E. Rajpert-De Meyts, Dysregulation of the mitosis-meiosis switch in testicular carcinoma in situ. J. Pathol. 229, 588-598 (2013)
114. S.M. Kraggerud, C.E. Hoei-Hansen, S. Alagaratnam, R.I. Skotheim, V.M. Abeler, E. Rajpert-De Meyts, R.A. Lothe, Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr. Rev. 34, 339-376 (2013)
115. P. Arnaud, Genomic imprinting in germ cells: imprints are under control. Reproduction 140, 411-423 (2010)
116. L. Mork, B. Capel, Oestrogen shuts the door on SOX9. BMC Biol. 8, 110 (2010)
117. P. Savage, J. Stebbing, M. Bower, T. Crook, Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin. Pract. Oncol. 6, 43-52 (2009)
118. J. Bartkova, C.J. Bakkenist, E. Rajpert-De Meyts, N.E. Skakkebaek, M. Sehested, J. Lukas, M.B. Kastan, J. Bartek, ATM activation in normal human tissues and testicular cancer. Cell Cycle 4, 838-845 (2005)
119. F. Cavallo, D.R. Feldman, M. Barchi, Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Int. J. Dev. Biol. 57, 273-280 (2013)
120. B. Köberle, J.R. Masters, J.A. Hartley, R.D. Wood, Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9, 273-276 (1999)
121. C. Welsh, R. Day, C. McGurk, J.R.W. Masters, R.D. Wood, B. Köberle, Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 110, 352-361 (2004)
122. B. Köberle, W. Brenner, A. Albers, S. Usanova, J.W. Thüroff, B. Kaina, ERCC1 and XPF expression in human testicular germ cell tumors. Oncol. Rep. 23, 223-227 (2010)
123. J. Mendoza, J. Martínez, C. Hernández, D. Pérez-Montiel, C. Castro, E. Fabián-Morales, M. Santibáñez, R. González-Barrios, J. Díaz- Chávez, M.A. Andonegui, N. Reynoso, L.F. Oñate, M.A. Jiménez, M. Núñez, R. Dyer, L.A. Herrera, Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br. J. Cancer 109, 68-75 (2013)
124. S. Bhana, A. Hewer, D.H. Phillips, D.R. Lloyd, p53-dependent global nucleoside excision repair of cisplatin-induced intrastand cross links in human cells. Mutagenesis 23, 131-136 (2008)
125. F. Cavallo, G. Graziani, C. Antinozzi, D.R. Feldman, J. Houldsworth, G.J. Bosl, R.S. Chaganti, M.E. Moynahan, M. Jasin, M. Barchi, Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One 7, e51563 (2012)
126. K.A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, J.-P. Pignon, T. Tursz, T. Le Chevalier, J.-C. Soria, DNA repair by ERCC1 in Non-Small-Cell Lung Cancer and cisplatin-based adjuvant chemotherapy. New Engl. J. Med. 355, 983-991 (2006)
127. E. Ribeiro, M. Ganzinelli, D. Andreis, R. Bertoni, R. Giardini, S.B. Fox, M. Broggini, A. Bottini, V. Zanoni, L. Bazzola, C. Foroni, D. Generali, G. Damia, Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS ONE 8, e66243 (2013)
128. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, G. Bepler, DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New Engl. J. Med. 356, 800-808 (2007)
129. R. Vélez-Cruz, D.G. Johnson, E2F1 and p53 transcription factors as accessory factors for nucleotide excision repair. Int. J. Mol. Sci. 13, 13554-13568 (2012)
130. S.R. Martens-de Kemp, S.U. Dalm, F.M.J. Wijnolts, A. Brink, R.J. Honeywell, G.J. Peters, B.J.M. Braakhuis, R.H. Brakenhoff, DNA-bound platinum is the major determinant of cisplatin sensitivity in head and necksquamous carcinoma cells. PLoS ONE 8, e61555 (2013)
131. L. Friboulet, K.A. Olaussen, J.P. Pignon, F.A. Shepherd, M.S. Tsao, S. Graziano, R. Kratzke, J.Y. Douillard, L. Seymour, R. Pirker, M. Filipits, F. André, E. Solary, F. Ponsonnailles, A. Robin, A. Stoclin, N. Dorvault, F. Commo, J. Adam, E. Vanhecke, P. Saulnier, J. Thomale, T. Le Chevalier, A. Dunant, V. Rousseau, G. Le Teuff, E. Brambilla, J.C. Soria, ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. New Engl. J. Med. 368, 1101-1110 (2013)
132. M.J.P. Welters, B.J.M. Braakhuis, A.J. Jacobs-Bergmans, A. Kegel, R.A. Baan, W.J.F. van der Vijgh, A.M.J. Fichtinger-Schepman, The potential of platinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy. Ann. Oncol. 10, 97-103 (1999)
133. X. Chen, L.J. Ko, L. Jayaraman, C. Prives, p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451 (1996)
134. J. Fan, J.R. Bertino, Modulation of cisplatinum cytotoxicity byp53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol. 56, 966-972 (1999)
135. J.C. Huang, D.B. Zamble, J.T. Reardon, S.J. Lippard, A. Sancar, HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U. S. A. 91, 10394-10398 (1994)
136. L. Jayaraman, N. Chandra Moorthy, K.G.K. Murthy, J.L. Manley, M. Bustin, C. Prives, High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12, 462-472 (1998)
137. Q. He, C.H. Liang, S.J. Lippard, Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. U. S. A. 97, 5768-5772 (2000)
138. G. Nagatani, M. Nomoto, H. Takano, T. Ise, K. Kato, T. Imamura, H. Izumi, K. Makishima, K. Kohno, Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res. 61, 1592-1597 (2001)
139. S.S. Lange, K.M. Vasquez, HMGB1: The jack-of-all-trades protein is a master DNA repair mechanic. Mol. Carcinog. 48, 571-580 (2009)
140. K.M. Livesey, R. Kang, P. Vernon, W. Buchser, P. Loughran, S.C. Watkins, L. Zhang, J.J. Manfredi, H.J. Zeh 3rd, L. Li, M.T. Lotze, D. Tang, p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 72, 1996-2005 (2012)
141. K.M. Livesey, R. Kang, H.J. Zeh III, M.T. Lotze, D. Tang, Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 8, 846-848 (2012)
142. D. Tang, R. Kang, H.J. Zeh III, M.T. Lotze, High-Mobility Group Box 1, oxidative stress, and disease. Antioxid. Redox Signal 14, 1315-1335 (2011)
143. S. Park, S.J. Lippard, Binding interaction of HMGB4 with cisplatin-modified DNA. Biochemistry 51, 6728-6737 (2012)
144. R. Franco, F. Esposito, M. Fedele, G. Liguori, G.M. Pierantoni, G. Botti, D. Tramontano, A. Fusco, P. Chieffi, Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours. J. Pathol. 214, 58-64 (2008)
145. G. D'Orazi, C. Rinaldo, S. Soddu, Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J. Exp. Clin. Cancer Res. 31, 63 (2012)
146. L.M.S. Resar, The High Mobility Group A1 gene: transforming inflammatory signals into cancer. Cancer Res. 70, 436-439 (2010)
147. I. Ben-Porath, M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, A. Regev, R.A. Weinberg, An embryonicstem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008)
148. F. Honecker, H. Wermann, F. Mayer, A.J.M. Gillis, H. Stoop, R.J.L.M. van Gurp, K. Oechsle, E. Steyerberg, J.T. Hartmann, W.N.M. Dinjens, J.W. Oosterhuis, C. Bokemeyer, L.H.J. Looijenga, Microsatellite instability, Mismatch Repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J. Clin. Oncol. 27, 2129-2136 (2009)
149. C.M. Ribic, D.J. Sergent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, R. Gryfe, L.E. Shepherd, D. Tu, M. Redston, S. Gallinger, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl. J. Med. 349, 247-257 (2003)
150. F.A. Sinicrope, M.R. Mahoney, T.C. Smyrk, S.N. Thibodeau, R.S. Warren, M.M. Bertagnolli, G.D. Nelson, R.M. Goldberg, D.J. Sargent, S.R. Alberts, Prognostic impact of deficient DNA Mismatch Repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J. Clin. Oncol. 31, 3664-3672 (2013)
151. D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, A. Nehmé, R.D. Christen, S.B. Howell, The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881-4886 (1996)
152. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, G.A. McArthur, BRIM-3 Study Group: improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011)
153. S.P. Wang, W.L. Wang, Y.L. Chang, C.T. Wu, Y.C. Chao, S.H. Kao, A. Yuan, C.W. Lin, S.C. Yang, W.K. Chan, K.C. Li, T.M. Hong, P.C. Yang, p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 11, 694-704 (2009)
154. R. Li, J. Liang, S. Ni, T. Zhou, X. Qing, H. Li, W. He, J. Chen, F. Li, Q. Zhuang, B. Qin, J. Xu, W. Li, J. Yang, Y. Gan, D. Qin, S. Feng, H. Song, D. Yang, B. Zhang, L. Zeng, L. Lai, M.A. Esteban, D. Pei, A mesenchymal-to- epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 7, 51-63 (2010)
155. S.H. Chiou, M.L. Wang, Y.T. Chou, C.J. Chen, C.F. Hong, W.J. Hsieh, H.T. Chang, Y.S. Chen, T.W. Lin, H.S. Hsu, C.W. Wu, Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70, 10433-10444 (2010)
156. M.K. Siu, E.S. Wong, D.S. Kong, H.Y. Chan, L. Jiang, O.G. Wong, E.W. Lam, K.K. Chan, H.Y. Ngan, X.F. Le, A.N. Cheung, Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 32, 3500-3509 (2013)
157. U.I. Ezeh, P.J. Turek, R.A. Reijo, A.T. Clark, Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104, 2255-2265 (2005)